{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:41:06Z","timestamp":1767840066062,"version":"3.49.0"},"reference-count":108,"publisher":"Zhejiang University Press","issue":"4","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Zhejiang Univ. Sci. B"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1631\/jzus.b2300779","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:36:10Z","timestamp":1741764970000},"page":"317-332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advancements in mechanisms and drug treatments for fibrodysplasia ossificans progressiva","\u8fdb\u884c\u6027\u9aa8\u5316\u6027\u7ea4\u7ef4\u53d1\u80b2\u4e0d\u826f\u7684\u53d1\u75c5\u673a\u5236\u53ca\u836f\u7269\u6cbb\u7597\u7684\u7814\u7a76\u8fdb\u5c55"],"prefix":"10.1631","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4035-8157","authenticated-orcid":false,"given":"Yijun","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1033-1626","authenticated-orcid":false,"given":"Ce","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2533-8150","authenticated-orcid":false,"given":"Hongchen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"635","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"785_CR1","doi-asserted-by":"publisher","first-page":"e54582","DOI":"10.7554\/eLife.54582","volume":"9","author":"S Aykul","year":"2020","unstructured":"Aykul S, Corpina RA, Goebel EJ, et al., 2020. Activin A forms a non-signaling complex with ACVR1 and type II Activin\/BMP receptors via its finger 2 tip loop. eLife, 9:e54582. https:\/\/doi.org\/10.7554\/eLife.54582","journal-title":"eLife"},{"issue":"12","key":"785_CR2","doi-asserted-by":"publisher","first-page":"e153792","DOI":"10.1172\/JCI153792","volume":"132","author":"S Aykul","year":"2022","unstructured":"Aykul S, Huang L, Wang LL, et al., 2022. Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1. J Clin Invest, 132(12):e153792. https:\/\/doi.org\/10.1172\/jci153792","journal-title":"J Clin Invest"},{"issue":"4","key":"785_CR3","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s10637-018-0668-8","volume":"37","author":"HM Babiker","year":"2019","unstructured":"Babiker HM, Byron SA, Hendricks WPD, et al., 2019. E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases. Invest New Drugs, 37(4): 636\u2013645. https:\/\/doi.org\/10.1007\/s10637-018-0668-8","journal-title":"Invest New Drugs"},{"issue":"22","key":"785_CR4","doi-asserted-by":"publisher","first-page":"e122958","DOI":"10.1172\/jci.insight.122958","volume":"3","author":"E Barruet","year":"2018","unstructured":"Barruet E, Morales BM, Cain CJ, et al., 2018. NF-\u03baB\/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification. JCI Insight, 3(22):e122958. https:\/\/doi.org\/10.1172\/jci.insight.122958","journal-title":"JCI Insight"},{"key":"785_CR5","volume-title":"Safety, tolerability, pharmacokinetics, and food effect of BLU-782 in healthy adults","author":"Blueprint Medicines Corporation","year":"2019","unstructured":"Blueprint Medicines Corporation, 2019. Safety, tolerability, pharmacokinetics, and food effect of BLU-782 in healthy adults. ClinicalTrials.gov ID NCT03858075. https:\/\/clinicaltrials.gov\/study\/NCT03858075"},{"key":"785_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.bone.2017.08.023","volume":"109","author":"TA Brennan","year":"2018","unstructured":"Brennan TA, Lindborg CM, Bergbauer CR, et al., 2018. Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP). Bone, 109:259\u2013266. https:\/\/doi.org\/10.1016\/j.bone.2017.08.023","journal-title":"Bone"},{"issue":"6","key":"785_CR7","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.stemcr.2015.10.020","volume":"5","author":"J Cai","year":"2015","unstructured":"Cai J, Orlova VV, Cai X, et al., 2015. Induced pluripotent stem cells to model human fibrodysplasia ossificans progressiva. Stem Cell Rep, 5(6):963\u2013970. https:\/\/doi.org\/10.1016\/j.stemcr.2015.10.020","journal-title":"Stem Cell Rep"},{"issue":"7","key":"785_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrd839","volume":"1","author":"R Capdeville","year":"2002","unstructured":"Capdeville R, Buchdunger E, Zimmermann J, et al., 2002. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov, 1(7):493\u2013502. https:\/\/doi.org\/10.1038\/nrd839","journal-title":"Nat Rev Drug Discov"},{"issue":"44","key":"785_CR9","doi-asserted-by":"publisher","first-page":"36990","DOI":"10.1074\/jbc.M112.365932","volume":"287","author":"A Chaikuad","year":"2012","unstructured":"Chaikuad A, Alfano I, Kerr G, et al., 2012. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J Biol Chem, 287(44):36990\u201336998. https:\/\/doi.org\/10.1074\/jbc.M112.365932","journal-title":"J Biol Chem"},{"issue":"9","key":"785_CR10","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/jbmr.2820","volume":"31","author":"SA Chakkalakal","year":"2016","unstructured":"Chakkalakal SA, Uchibe K, Convente MR, et al., 2016. Palovarotene inhibits heterotopic ossification and maintains limb mobility and growth in mice with the human ACVR1R206H fibrodysplasia ossificans progressiva (FOP) mutation. J Bone Miner Res, 31(9):1666\u20131675. https:\/\/doi.org\/10.1002\/jbmr.2820","journal-title":"J Bone Miner Res"},{"issue":"Suppl1","key":"785_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2020-136138","volume":"136","author":"YY Chen","year":"2020","unstructured":"Chen YY, Stubbs MC, Pusey M, et al., 2020. Characterization of INCB00928, a potent and selective ALK2 inhibitor for the treatment of anemia. Blood, 136(Suppl 1):52. https:\/\/doi.org\/10.1182\/blood-2020-136138","journal-title":"Blood"},{"issue":"9","key":"785_CR12","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.3390\/ijms22094534","volume":"22","author":"W Chiu","year":"2021","unstructured":"Chiu W, Lin TY, Chang YC, et al., 2021. An update on gene therapy for inherited retinal dystrophy: experience in leber congenital amaurosis clinical trials. Int J Mol Sci, 22(9):4534. https:\/\/doi.org\/10.3390\/ijms22094534","journal-title":"Int J Mol Sci"},{"issue":"2","key":"785_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/jbmr.3304","volume":"33","author":"MR Convente","year":"2018","unstructured":"Convente MR, Chakkalakal SA, Yang EJ, et al., 2018. Depletion of mast cells and macrophages impairs heterotopic ossification in an Acvr1R206H mouse model of fibrodysplasia ossificans progressiva. J Bone Miner Res, 33(2):269\u2013282. https:\/\/doi.org\/10.1002\/jbmr.3304","journal-title":"J Bone Miner Res"},{"issue":"15","key":"785_CR14","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1016\/j.bmcl.2008.06.052","volume":"18","author":"GD Cuny","year":"2008","unstructured":"Cuny GD, Yu PB, Laha JK, et al., 2008. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett, 18(15):4388\u20134392. https:\/\/doi.org\/10.1016\/j.bmcl.2008.06.052","journal-title":"Bioorg Med Chem Lett"},{"key":"785_CR15","first-page":"320","volume":"37","author":"R de Ruiter","year":"2022","unstructured":"de Ruiter R, Groot T, Schoenmaker T, et al., 2022. Fibroblasts from patients with fibrodysplasia ossificans progressiva exhibit increased activin a production. J Bone Miner Res, 37:320\u2013320.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"785_CR16","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.3390\/ijms24032299","volume":"24","author":"RD de Ruiter","year":"2023","unstructured":"de Ruiter RD, Wisse LE, Schoenmaker T, et al., 2023. TGF-beta induces activin a production in dermal fibroblasts derived from patients with fibrodysplasia ossificans progressiva. Int J Mol Sci, 24(3):2299. https:\/\/doi.org\/10.3390\/ijms24032299","journal-title":"Int J Mol Sci"},{"issue":"4","key":"785_CR17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/cyto.b.21594","volume":"94","author":"G del Zotto","year":"2018","unstructured":"del Zotto G, Antonini F, Azzari I, et al., 2018. Peripheral blood mononuclear cell immunophenotyping in fibrodysplasia ossificans progressiva patients: evidence for monocyte DNAM1 up-regulation. Cytometry B Clin Cytom, 94(4): 613\u2013622. https:\/\/doi.org\/10.1002\/cyto.b.21594","journal-title":"Cytometry B Clin Cytom"},{"issue":"366","key":"785_CR18","doi-asserted-by":"publisher","first-page":"366ra163","DOI":"10.1126\/scitranslmed.aaf1090","volume":"8","author":"D Dey","year":"2016","unstructured":"Dey D, Bagarova J, Hatsell SJ, et al., 2016. Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification. Sci Transl Med, 8(366):366ra163. https:\/\/doi.org\/10.1126\/scitranslmed.aaf1090","journal-title":"Sci Transl Med"},{"issue":"11","key":"785_CR19","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1016\/j.bmcl.2013.03.113","volume":"23","author":"DW Engers","year":"2013","unstructured":"Engers DW, Frist AY, Lindsley CW, et al., 2013. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett, 23(11): 3248\u20133252. https:\/\/doi.org\/10.1016\/j.bmcl.2013.03.113","journal-title":"Bioorg Med Chem Lett"},{"issue":"18","key":"785_CR20","doi-asserted-by":"publisher","first-page":"127418","DOI":"10.1016\/j.bmcl.2020.127418","volume":"30","author":"DW Engers","year":"2020","unstructured":"Engers DW, Bollinger SR, Felts AS, et al., 2020. Discovery, synthesis and characterization of a series of 7-aryl-imidazo [1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors. Bioorg Med Chem Lett, 30(18): 127418. https:\/\/doi.org\/10.1016\/j.bmcl.2020.127418","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"785_CR21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ccell.2020.02.002","volume":"37","author":"J Fortin","year":"2020","unstructured":"Fortin J, Tian RX, Zarrabi I, et al., 2020. Mutant ACVR1 arrests glial cell differentiation to drive tumorigenesis in pediatric gliomas. Cancer Cell, 37(3):308\u2013323.e12. https:\/\/doi.org\/10.1016\/j.ccell.2020.02.002","journal-title":"Cancer Cell"},{"issue":"8","key":"785_CR22","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1002\/jbmr.2819","volume":"31","author":"B G\u00e1mez","year":"2016","unstructured":"G\u00e1mez B, Rodr\u00edguez-Carballo E, Graupera M, et al., 2016. Class I PI-3-kinase signaling is critical for bone formation through regulation of SMAD1 activity in osteoblasts. J Bone Miner Res, 31(8):1617\u20131630. https:\/\/doi.org\/10.1002\/jbmr.2819","journal-title":"J Bone Miner Res"},{"issue":"3","key":"785_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1359\/jbmr.090830","volume":"25","author":"RA Hannon","year":"2010","unstructured":"Hannon RA, Clack G, Rimmer M, et al., 2010. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. J Bone Miner Res, 25(3):463\u2013471. https:\/\/doi.org\/10.1359\/jbmr.090830","journal-title":"J Bone Miner Res"},{"issue":"2","key":"785_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1021\/cb9002865","volume":"5","author":"JJ Hao","year":"2010","unstructured":"Hao JJ, Ho JN, Lewis JA, et al., 2010. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem Biol, 5(2): 245\u2013253. https:\/\/doi.org\/10.1021\/cb9002865","journal-title":"ACS Chem Biol"},{"issue":"303","key":"785_CR25","doi-asserted-by":"publisher","first-page":"303ra137","DOI":"10.1126\/scitranslmed.aac4358","volume":"7","author":"SJ Hatsell","year":"2015","unstructured":"Hatsell SJ, Idone V, Wolken DMA, et al., 2015. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med, 7(303):303ra137. https:\/\/doi.org\/10.1126\/scitranslmed.aac4358","journal-title":"Sci Transl Med"},{"key":"785_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12969-019-0386-6","volume":"17","author":"R Haviv","year":"2019","unstructured":"Haviv R, Moshe V, de Benedetti F, et al., 2019. Is fibrodysplasia ossificans progressiva an interleukin-1 driven autoinflammatory syndrome? Pediatr Rheumatol, 17:84. https:\/\/doi.org\/10.1186\/s12969-019-0386-6","journal-title":"Pediatr Rheumatol"},{"issue":"22","key":"785_CR27","doi-asserted-by":"publisher","first-page":"6465","DOI":"10.1021\/jm060434q","volume":"49","author":"LF Hennequin","year":"2006","unstructured":"Hennequin LF, Allen J, Breed J, et al., 2006. N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src\/Abl kinase inhibitor. J Med Chem, 49(22):6465\u20136488. https:\/\/doi.org\/10.1021\/jm060434q","journal-title":"J Med Chem"},{"issue":"4","key":"785_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/01.tp.0000251376.75347.b4","volume":"83","author":"KE Herbert","year":"2007","unstructured":"Herbert KE, Walkley CR, Winkler IG, et al., 2007. Granulocyte colony-stimulating factor and an RAR\u03b1 specific agonist, VTP195183, synergize to enhance the mobilization of hematopoietic progenitor cells. Transplantation, 83(4):375\u2013384. https:\/\/doi.org\/10.1097\/01.tp.0000251376.75347.b4","journal-title":"Transplantation"},{"issue":"3","key":"785_CR29","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s12015-020-10103-9","volume":"17","author":"S Hildebrandt","year":"2021","unstructured":"Hildebrandt S, Kampfrath B, Fischer K, et al., 2021. Activina induced SMAD1\/5 signaling in an iPSC derived EC model of fibrodysplasia ossificans progressiva (FOP) can be rescued by the drug candidate saracatinib. Stem Cell Rev Rep, 17(3):1039\u20131052. https:\/\/doi.org\/10.1007\/s12015-020-10103-9","journal-title":"Stem Cell Rev Rep"},{"issue":"9","key":"785_CR30","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1172\/JCI93521","volume":"127","author":"K Hino","year":"2017","unstructured":"Hino K, Horigome K, Nishio M, et al., 2017. Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva. J Clin Invest, 127(9):3339\u20133352. https:\/\/doi.org\/10.1172\/JCI93521","journal-title":"J Clin Invest"},{"issue":"5","key":"785_CR31","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.stemcr.2018.10.007","volume":"11","author":"K Hino","year":"2018","unstructured":"Hino K, Zhao CZ, Horigome K, et al., 2018. An mTOR signaling modulator suppressed heterotopic ossification of fibrodysplasia ossificans progressiva. Stem Cell Rep, 11(5): 1106\u20131119. https:\/\/doi.org\/10.1016\/j.stemcr.2018.10.007","journal-title":"Stem Cell Rep"},{"issue":"10","key":"785_CR32","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, et al., 2017. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med, 376(10):917\u2013927. https:\/\/doi.org\/10.1056\/NEJMoa1609324","journal-title":"N Engl J Med"},{"key":"785_CR33","doi-asserted-by":"publisher","first-page":"101177","DOI":"10.1016\/j.bonr.2022.101177","volume":"16","author":"S Hrkac","year":"2022","unstructured":"Hrkac S, Novak R, Salai G, et al., 2022. Heterotopic ossification vs. fracture healing: extracellular vesicle cargo proteins shed new light on bone formation. Bone Rep, 16:101177. https:\/\/doi.org\/10.1016\/j.bonr.2022.101177","journal-title":"Bone Rep"},{"issue":"6","key":"785_CR34","doi-asserted-by":"publisher","first-page":"4580","DOI":"10.1002\/jcp.30183","volume":"236","author":"Y Hu","year":"2021","unstructured":"Hu Y, Hao XQ, Liu CW, et al., 2021. Acvr1 deletion in osteoblasts impaired mandibular bone mass through compromised osteoblast differentiation and enhanced sRANKL-induced osteoclastogenesis. J Cell Physiol, 236(6):4580\u20134591. https:\/\/doi.org\/10.1002\/jcp.30183","journal-title":"J Cell Physiol"},{"key":"785_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41413-019-0075-6","volume":"7","author":"C Hwang","year":"2019","unstructured":"Hwang C, Marini S, Huber AK, et al., 2019. Mesenchymal VEGFA induces aberrant differentiation in heterotopic ossification. Bone Res, 7:36. https:\/\/doi.org\/10.1038\/s41413-019-0075-6","journal-title":"Bone Res"},{"issue":"14","key":"785_CR36","doi-asserted-by":"publisher","first-page":"e158996","DOI":"10.1172\/jci.insight.158996","volume":"7","author":"CD Hwang","year":"2022","unstructured":"Hwang CD, Pagani CA, Nunez JH, et al., 2022. Contemporary perspectives on heterotopic ossification. JCI Insight, 7(14): e158996. https:\/\/doi.org\/10.1172\/jci.insight.158996","journal-title":"JCI Insight"},{"key":"785_CR37","volume-title":"DS-6016a","author":"IFOPA","year":"2022","unstructured":"IFOPA, 2022. DS-6016a. https:\/\/www.ifopa.org\/ds_6016a"},{"key":"785_CR38","volume-title":"To assess the efficacy, safety, and tolerability of INCB000928 in participants with fibrodysplasia ossificans progressiva (progress)","author":"Incyte Corporation","year":"2024","unstructured":"Incyte Corporation, 2024. To assess the efficacy, safety, and tolerability of INCB000928 in participants with fibrodysplasia ossificans progressiva (progress). ClinicalTrials.gov ID NCT05090891. https:\/\/clinicaltrials.gov\/study\/NCT05090891"},{"key":"785_CR39","doi-asserted-by":"publisher","first-page":"100757","DOI":"10.1016\/j.tcam.2022.100757","volume":"52","author":"KL Jacobsen","year":"2023","unstructured":"Jacobsen KL, Wiebe V, Davidson AP, et al., 2023. Use of enrofloxacin and hydrotherapy in the management of fibrodysplasia ossificans progressiva (FOP) in a Savannah cat. Top Companion Anim Med, 52:100757. https:\/\/doi.org\/10.1016\/j.tcam.2022.100757","journal-title":"Top Companion Anim Med"},{"issue":"5","key":"785_CR40","doi-asserted-by":"publisher","first-page":"dev188490","DOI":"10.1242\/dev.188490","volume":"148","author":"SJ Jia","year":"2021","unstructured":"Jia SJ, Meng AM, 2021. TGF\u03b2 family signaling and development. Development, 148(5):dev188490. https:\/\/doi.org\/10.1242\/dev.188490","journal-title":"Development"},{"issue":"20","key":"785_CR41","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1016\/j.bmcl.2018.09.006","volume":"28","author":"JK Jiang","year":"2018","unstructured":"Jiang JK, Huang XL, Shamim K, et al., 2018. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett, 28(20):3356\u20133362. https:\/\/doi.org\/10.1016\/j.bmcl.2018.09.006","journal-title":"Bioorg Med Chem Lett"},{"key":"785_CR42","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.bone.2017.07.019","volume":"109","author":"FS Kaplan","year":"2018","unstructured":"Kaplan FS, Andolina JR, Adamson PC, et al., 2018a. Early clinical observations on the use of imatinib mesylate in FOP: a report of seven cases. Bone, 109:276\u2013280. https:\/\/doi.org\/10.1016\/j.bone.2017.07.019","journal-title":"Bone"},{"key":"785_CR43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.bone.2017.12.011","volume":"109","author":"FS Kaplan","year":"2018","unstructured":"Kaplan FS, Zeitlin L, Dunn SP, et al., 2018b. Acute and chronic rapamycin use in patients with fibrodysplasia ossificans progressiva: a report of two cases. Bone, 109:281\u2013284. https:\/\/doi.org\/10.1016\/j.bone.2017.12.011","journal-title":"Bone"},{"issue":"7","key":"785_CR44","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/gt.2011.152","volume":"19","author":"J Kaplan","year":"2012","unstructured":"Kaplan J, Kaplan FS, Shore EM, 2012. Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting. Gene Ther, 19(7):786\u2013790. https:\/\/doi.org\/10.1038\/gt.2011.152","journal-title":"Gene Ther"},{"key":"785_CR45","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1038\/s41467-023-38746-5","volume":"14","author":"T Katagiri","year":"2023","unstructured":"Katagiri T, Tsukamoto S, Kuratani M, et al., 2023. A blocking monoclonal antibody reveals dimerization of intracellular domains of ALK2 associated with genetic disorders. Nat Commun, 14:2960. https:\/\/doi.org\/10.1038\/s41467-023-38746-5","journal-title":"Nat Commun"},{"issue":"5","key":"785_CR46","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41551-023-01011-7","volume":"7","author":"M Kawamata","year":"2023","unstructured":"Kawamata M, Suzuki HI, Kimura R, et al., 2023. Optimization of Cas9 activity through the addition of cytosine extensions to single-guide RNAs. Nat Biomed Eng, 7(5):672\u2013691. https:\/\/doi.org\/10.1038\/s41551-023-01011-7","journal-title":"Nat Biomed Eng"},{"issue":"9","key":"785_CR47","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/biomedicines8090325","volume":"8","author":"H Kitoh","year":"2020","unstructured":"Kitoh H, 2020. Clinical aspects and current therapeutic approaches for FOP. Biomedicines, 8(9):325. https:\/\/doi.org\/10.3390\/biomedicines8090325","journal-title":"Biomedicines"},{"issue":"12","key":"785_CR48","doi-asserted-by":"publisher","first-page":"e153795","DOI":"10.1172\/JCI153795","volume":"132","author":"JB Lees-Shepard","year":"2022","unstructured":"Lees-Shepard JB, Stoessel SJ, Chandler JT, et al., 2022. An anti-ACVR1 antibody exacerbates heterot ossification by fibro-adipogenic progenitors in fibrodysplasia ossificans progressiva mice. J Clinical Invest, 132(12):e153795. https:\/\/doi.org\/10.1172\/jci153795","journal-title":"J Clinical Invest"},{"key":"785_CR49","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1038\/s41467-020-17093-9","volume":"11","author":"KH Lim","year":"2020","unstructured":"Lim KH, Han Z, Jeon HY, et al., 2020. Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression. Nat Commun, 11:3501. https:\/\/doi.org\/10.1038\/s41467-020-17093-9","journal-title":"Nat Commun"},{"issue":"1","key":"785_CR50","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1566524016666151222142446","volume":"16","author":"Y Luo","year":"2016","unstructured":"Luo Y, Alsamarah A, Zhang K, et al., 2016. Development of new therapeutic agents for fibrodysplasia ossificans progressiva. Curr Mol Med, 16(1):4\u201311. https:\/\/doi.org\/10.2174\/1566524016666151222142446","journal-title":"Curr Mol Med"},{"key":"785_CR51","doi-asserted-by":"publisher","first-page":"175109","DOI":"10.1016\/j.ejphar.2022.175109","volume":"928","author":"D Mao","year":"2022","unstructured":"Mao D, Mi JY, Pan XY, et al., 2022. Galunisertib attenuates progression of trauma-induced heterotopic ossification via blockage of Smad2\/3 signaling in mice. Eur J Pharmacol, 928:175109. https:\/\/doi.org\/10.1016\/j.ejphar.2022.175109","journal-title":"Eur J Pharmacol"},{"key":"785_CR52","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/978-1-4939-8651-4_32","volume-title":"Exon Skipping and Inclusion Therapies: Methods and Protocols","author":"R Maruyama","year":"2018","unstructured":"Maruyama R, Yokota T, 2018. Morpholino-mediated exon skipping targeting human ACVR1\/ALK2 for fibrodysplasia ossificans progressiva. In: Yokota T, Maruyama R (Eds.), Exon Skipping and Inclusion Therapies: Methods and Protocols. Humana Press, New York, p.497\u2013502. https:\/\/doi.org\/10.1007\/978-1-4939-8651-4_32"},{"issue":"3","key":"785_CR53","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1089\/nat.2021.0009","volume":"32","author":"R Maruyama","year":"2022","unstructured":"Maruyama R, Nguyen Q, Roshmi RR, et al., 2022. Allele-selective LNA gapmers for the treatment of fibrodysplasia ossificans progressiva knock down the pathogenic ACVR1R206H transcript and inhibit osteogenic differentiation. Nucl Acid Ther, 32(3):185\u2013193. https:\/\/doi.org\/10.1089\/nat.2021.0009","journal-title":"Nucl Acid Ther"},{"issue":"10","key":"785_CR54","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1007\/s11010-022-04446-9","volume":"477","author":"XM Meng","year":"2022","unstructured":"Meng XM, Wang HT, Hao JJ, 2022. Recent progress in drug development for fibrodysplasia ossificans progressiva. Mol Cell Biochem, 477(10):2327\u20132334. https:\/\/doi.org\/10.1007\/s11010-022-04446-9","journal-title":"Mol Cell Biochem"},{"issue":"6","key":"785_CR55","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1021\/cb300655w","volume":"8","author":"AH Mohedas","year":"2013","unstructured":"Mohedas AH, Xing XC, Armstrong KA, et al., 2013. Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol, 8(6):1291\u20131302. https:\/\/doi.org\/10.1021\/cb300655w","journal-title":"ACS Chem Biol"},{"issue":"2","key":"785_CR56","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/bfgp\/elac026","volume":"22","author":"G Nagar","year":"2023","unstructured":"Nagar G, Mittal P, Gupta SRR, et al., 2023. Multi-omics therapeutic perspective on ACVR1 gene: from genetic alterations to potential targeting. Brief Funct Genomics, 22(2): 123\u2013142. https:\/\/doi.org\/10.1093\/bfgp\/elac026","journal-title":"Brief Funct Genomics"},{"issue":"7","key":"785_CR57","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1021\/acsmedchemlett.2c00206","volume":"13","author":"MH Nguyen","year":"2022","unstructured":"Nguyen MH, Atasoylu O, Wu LX, et al., 2022. Discovery of novel pyrazolopyrimidines as potent, selective, and orally bioavailable inhibitors of ALK2. ACS Med Chem Lett, 13(7): 1159\u20131164. https:\/\/doi.org\/10.1021\/acsmedchemlett.2c00206","journal-title":"ACS Med Chem Lett"},{"key":"785_CR58","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12969-023-00856-1","volume":"21","author":"IP Nikishina","year":"2023","unstructured":"Nikishina IP, Arsenyeva SV, Matkava VG, et al., 2023. Successful experience of tofacitinib treatment in patients with fibrodysplasia ossificans progressiva. Pediatr Rheumatol, 21:92. https:\/\/doi.org\/10.1186\/s12969-023-00856-1","journal-title":"Pediatr Rheumatol"},{"key":"785_CR59","doi-asserted-by":"publisher","first-page":"127783","DOI":"10.1016\/j.bmcl.2021.127783","volume":"35","author":"S Ohte","year":"2021","unstructured":"Ohte S, Yamazaki H, Takahashi O, et al., 2021. Inhibitory effects of sesquiterpene lactones from the indonesian marine sponge Lamellodysidea cf. herbacea on bone morphogenetic protein-induced osteoblastic differentiation. Bioorg Med Chem Lett, 35:127783. https:\/\/doi.org\/10.1016\/j.bmcl.2021.127783","journal-title":"Bioorg Med Chem Lett"},{"key":"785_CR60","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.bone.2017.08.010","volume":"109","author":"M Pacifici","year":"2018","unstructured":"Pacifici M, 2018. Retinoid roles and action in skeletal development and growth provide the rationale for an ongoing heterotopic ossification prevention trial. Bone, 109:267\u2013275. https:\/\/doi.org\/10.1016\/j.bone.2017.08.010","journal-title":"Bone"},{"issue":"3","key":"785_CR61","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s11914-021-00673-z","volume":"19","author":"JL Pierce","year":"2021","unstructured":"Pierce JL, Perrien DS, 2021. Do interactions of vitamin D3 and BMP signaling hold implications in the pathogenesis of fibrodysplasia ossificans progressiva? Curr Osteoporos Rep, 19(3):358\u2013367. https:\/\/doi.org\/10.1007\/s11914-021-00673-z","journal-title":"Curr Osteoporos Rep"},{"issue":"11","key":"785_CR62","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.3390\/cells10113245","volume":"10","author":"RJ Pignolo","year":"2021","unstructured":"Pignolo RJ, Pacifici M, 2021. Retinoid agonists in the targeting of heterotopic ossification. Cells, 10(11):3245. https:\/\/doi.org\/10.3390\/cells10113245","journal-title":"Cells"},{"key":"785_CR63","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3389\/fendo.2019.00908","volume":"10","author":"RJ Pignolo","year":"2020","unstructured":"Pignolo RJ, Wang HT, Kaplan FS, 2020. Fibrodysplasia ossificans progressiva (FOP): a segmental progeroid syndrome. Front Endocrinol, 10:908. https:\/\/doi.org\/10.3389\/fendo.2019.00908","journal-title":"Front Endocrinol"},{"key":"785_CR64","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13023-022-02224-w","volume":"17","author":"RJ Pignolo","year":"2022","unstructured":"Pignolo RJ, Bedford-Gay C, Cali A, et al., 2022a. Current challenges and opportunities in the care of patients with fibrodysplasia ossificans progressiva (FOP): an international, multi-stakeholder perspective. Orphanet J Rare Dis, 17:168. https:\/\/doi.org\/10.1186\/s13023-022-02224-w","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"785_CR65","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/jbmr.4492","volume":"37","author":"RJ Pignolo","year":"2022","unstructured":"Pignolo RJ, McCarrick-Walmsley R, Wang HT, et al., 2022b. Plasma-soluble biomarkers for fibrodysplasia ossificans progressiva (FOP) reflect acute and chronic inflammatory states. J Bone Miner Res, 37(3):475\u2013483. https:\/\/doi.org\/10.1002\/jbmr.4492","journal-title":"J Bone Miner Res"},{"issue":"3","key":"785_CR66","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/jbmr.4762","volume":"38","author":"RJ Pignolo","year":"2023","unstructured":"Pignolo RJ, Hsiao EC, al Mukaddam M, et al., 2023. Reduction of new heterotopic ossification (HO) in the open-label, phase 3 MOVE trial of palovarotene for fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res, 38(3): 381\u2013394. https:\/\/doi.org\/10.1002\/jbmr.4762","journal-title":"J Bone Miner Res"},{"issue":"11","key":"785_CR67","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1016\/j.ajpath.2017.07.010","volume":"187","author":"AT Qureshi","year":"2017","unstructured":"Qureshi AT, Dey D, Sanders EM, et al., 2017. Inhibition of mammalian target of rapamycin signaling with rapamycin prevents trauma-induced heterotopic ossification. Am J Pathol, 187(11):2536\u20132545. https:\/\/doi.org\/10.1016\/j.ajpath.2017.07.010","journal-title":"Am J Pathol"},{"issue":"8","key":"785_CR68","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.annonc.2020.05.001","volume":"31","author":"HS Rugo","year":"2020","unstructured":"Rugo HS, Andr\u00e9 F, Yamashita T, et al., 2020. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol, 31(8):1001\u20131010. https:\/\/doi.org\/10.1016\/j.annonc.2020.05.001","journal-title":"Ann Oncol"},{"issue":"11","key":"785_CR69","doi-asserted-by":"publisher","first-page":"e10230","DOI":"10.1002\/jbm4.10230","volume":"3","author":"G S\u00e1nchez-Duffhues","year":"2019","unstructured":"S\u00e1nchez-Duffhues G, Williams E, Benderitter P, et al., 2019. Development of macrocycle kinase inhibitors for ALK2 using fibrodysplasia ossificans progressiva-derived endothelial cells. JBMR Plus, 3(11):e10230. https:\/\/doi.org\/10.1002\/jbm4.10230","journal-title":"JBMR Plus"},{"issue":"4","key":"785_CR70","doi-asserted-by":"publisher","first-page":"e62721","DOI":"10.1371\/journal.pone.0062721","volume":"8","author":"CE Sanvitale","year":"2013","unstructured":"Sanvitale CE, Kerr G, Chaikuad A, et al., 2013. A new class of small molecule inhibitor of BMP signaling. PLoS ONE, 8(4):e62721. https:\/\/doi.org\/10.1371\/journal.pone.0062721","journal-title":"PLoS ONE"},{"issue":"20","key":"785_CR71","doi-asserted-by":"publisher","first-page":"11411","DOI":"10.1021\/acsomega.9b04245","volume":"5","author":"T Sato","year":"2020","unstructured":"Sato T, Sekimata K, Sakai N, et al., 2020. Structural basis of activin receptor-like kinase 2 (R206H) inhibition by bisheteroaryl pyrazole-based inhibitors for the treatment of fibrodysplasia ossificans progressiva identified by the integration of ligand-based and structure-based drug design approaches. ACS Omega, 5(20):11411\u201311423. https:\/\/doi.org\/10.1021\/acsomega.9b04245","journal-title":"ACS Omega"},{"issue":"7","key":"785_CR72","doi-asserted-by":"publisher","first-page":"6822","DOI":"10.3390\/ijms24076822","volume":"24","author":"T Schoenmaker","year":"2023","unstructured":"Schoenmaker T, Zwaak J, Loos BG, et al., 2023. Transcriptomic differences underlying the activin-A induced large osteoclast formation in both healthy control and fibrodysplasia ossificans progressiva osteoclasts. Int J Mole Sci, 24(7): 6822. https:\/\/doi.org\/10.3390\/ijms24076822","journal-title":"Int J Mole Sci"},{"key":"785_CR73","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bone.2017.11.016","volume":"109","author":"DM She","year":"2018","unstructured":"She DM, Zhang KQ, 2018. Fibrodysplasia ossificans progressiva in China. Bone, 109:101\u2013103. https:\/\/doi.org\/10.1016\/j.bone.2017.11.016","journal-title":"Bone"},{"issue":"7","key":"785_CR74","doi-asserted-by":"publisher","first-page":"e69096","DOI":"10.1371\/journal.pone.0069096","volume":"8","author":"ST Shi","year":"2013","unstructured":"Shi ST, Cai J, de Gorter DJJ, et al., 2013. Antisenseoligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva. PLoS ONE, 8(7): e69096. https:\/\/doi.org\/10.1371\/journal.pone.0069096","journal-title":"PLoS ONE"},{"issue":"2","key":"785_CR75","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/jor.20985","volume":"28","author":"K Shimono","year":"2010","unstructured":"Shimono K, Morrison TN, Tung WE, et al., 2010. Inhibition of ectopic bone formation by a selective retinoic acid receptor \u03b1-agonist: a new therapy for heterotopic ossification? J Orthop Res, 28(2):271\u2013277. https:\/\/doi.org\/10.1002\/jor.20985","journal-title":"J Orthop Res"},{"issue":"4","key":"785_CR76","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nm.2334","volume":"17","author":"K Shimono","year":"2011","unstructured":"Shimono K, Tung WE, Macolino C, et al., 2011. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-\u03b3 agonists. Nat Med, 17(4):454\u2013460. https:\/\/doi.org\/10.1038\/nm.2334","journal-title":"Nat Med"},{"issue":"5","key":"785_CR77","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ng1783","volume":"38","author":"EM Shore","year":"2006","unstructured":"Shore EM, Xu MQ, Feldman GJ, et al., 2006. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet, 38(5):525\u2013527. https:\/\/doi.org\/10.1038\/ng1783","journal-title":"Nat Genet"},{"key":"785_CR78","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/orr.s337491","volume":"14","author":"BJ Smilde","year":"2022","unstructured":"Smilde BJ, Botman E, de Ruiter R, et al., 2022. Monitoring and management of fibrodysplasia ossificans progressiva: current perspectives. Orthop Res Rev, 14:113\u2013120. https:\/\/doi.org\/10.2147\/orr.s337491","journal-title":"Orthop Res Rev"},{"issue":"29","key":"785_CR79","doi-asserted-by":"publisher","first-page":"22542","DOI":"10.1074\/jbc.M109.094557","volume":"285","author":"GA Song","year":"2010","unstructured":"Song GA, Kim HJ, Woo KM, et al., 2010. Molecular consequences of the ACVR1R206H mutation of fibrodysplasia ossificans progressiva. J Biol Chem, 285(29):22542\u201322553. https:\/\/doi.org\/10.1074\/jbc.M109.094557","journal-title":"J Biol Chem"},{"key":"785_CR80","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41536-021-00201-8","volume":"7","author":"A Stanley","year":"2022","unstructured":"Stanley A, Tichy ED, Kocan J, et al., 2022. Dynamics of skeletal muscle-resident stem cells during myogenesis in fibrodysplasia ossificans progressiva. npj Regen Med, 7:5. https:\/\/doi.org\/10.1038\/s41536-021-00201-8","journal-title":"npj Regen Med"},{"key":"785_CR81","doi-asserted-by":"publisher","first-page":"115517","DOI":"10.1016\/j.bone.2020.115517","volume":"139","author":"AL Strong","year":"2020","unstructured":"Strong AL, Spreadborough PJ, Pagani CA, et al., 2020. Small molecule inhibition of non-canonical (TAK1-mediated) BMP signaling results in reduced chondrogenic ossification and heterotopic ossification in a rat model of blast-associated combat-related lower limb trauma. Bone, 139: 115517. https:\/\/doi.org\/10.1016\/j.bone.2020.115517","journal-title":"Bone"},{"key":"785_CR82","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.3389\/fimmu.2019.01640","volume":"10","author":"M Tirone","year":"2019","unstructured":"Tirone M, Giovenzana A, Vallone A, et al., 2019. Severe heterotopic ossification in the skeletal muscle and endothelial cells recruitment to chondrogenesis are enhanced by monocyte\/macrophage depletion. Front Immunol, 10:1640. https:\/\/doi.org\/10.3389\/fimmu.2019.01640","journal-title":"Front Immunol"},{"issue":"1","key":"785_CR83","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/dvdy.387","volume":"251","author":"OW Towler","year":"2022","unstructured":"Towler OW, Shore EM, 2022. BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP). Dev Dyn, 251(1): 144\u2013157. https:\/\/doi.org\/10.1002\/dvdy.387","journal-title":"Dev Dyn"},{"key":"785_CR84","doi-asserted-by":"publisher","first-page":"128667","DOI":"10.1016\/j.bmcl.2022.128667","volume":"64","author":"T Ullrich","year":"2022","unstructured":"Ullrich T, Arista L, Weiler S, et al., 2022. Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of activin receptor-like kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva. Bioorg Med Chem Lett, 64:128667. https:\/\/doi.org\/10.1016\/j.bmcl.2022.128667","journal-title":"Bioorg Med Chem Lett"},{"issue":"12","key":"785_CR85","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1002\/jbmr.3235","volume":"32","author":"J Upadhyay","year":"2017","unstructured":"Upadhyay J, Xie LQ, Huang L, et al., 2017. The expansion of heterotopic bone in fibrodysplasia ossificans progressiva is activin A-dependent. J Bone Miner Res, 32(12): 2489\u20132499. https:\/\/doi.org\/10.1002\/jbmr.3235","journal-title":"J Bone Miner Res"},{"issue":"9","key":"785_CR86","doi-asserted-by":"publisher","first-page":"e10567","DOI":"10.15252\/emmm.201910567","volume":"11","author":"JA Valer","year":"2019","unstructured":"Valer JA, S\u00e1nchez-de-Diego C, G\u00e1mez B, et al., 2019. Inhibition of phosphatidylinositol 3-kinase \u03b1 (PI3\u03b1) prevents heterotopic ossification. EMBO Mol Med, 11(9):e10567. https:\/\/doi.org\/10.15252\/emmm.201910567","journal-title":"EMBO Mol Med"},{"issue":"2","key":"785_CR87","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3390\/biomedicines9020213","volume":"9","author":"F Ventura","year":"2021","unstructured":"Ventura F, Williams E, Ikeya M, et al., 2021. Challenges and opportunities for drug repositioning in fibrodysplasia ossificans progressiva. Biomedicines, 9(2):213. https:\/\/doi.org\/10.3390\/biomedicines9020213","journal-title":"Biomedicines"},{"issue":"9","key":"785_CR88","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/jbmr.2848","volume":"31","author":"HT Wang","year":"2016","unstructured":"Wang HT, Lindborg C, Lounev V, et al., 2016. Cellular hypoxia promotes heterotopic ossification by amplifying BMP signaling. J Bone Miner Res, 31(9):1652\u20131665. https:\/\/doi.org\/10.1002\/jbmr.2848","journal-title":"J Bone Miner Res"},{"key":"785_CR89","doi-asserted-by":"publisher","first-page":"115978","DOI":"10.1016\/j.bone.2021.115978","volume":"149","author":"HT Wang","year":"2021","unstructured":"Wang HT, de Cunto CL, Pignolo RJ, et al., 2021. Spatial patterns of heterotopic ossification in fibrodysplasia ossificans progressiva correlate with anatomic temperature gradients. Bone, 149:115978. https:\/\/doi.org\/10.1016\/j.bone.2021.115978","journal-title":"Bone"},{"issue":"1","key":"785_CR90","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/jbmr.4458","volume":"37","author":"HT Wang","year":"2022","unstructured":"Wang HT, Zhang Q, Kaplan FS, et al., 2022. Clearance of senescent cells from injured muscle abrogates heterotopic ossification in mouse models of fibrodysplasia ossificans progressiva. J Bone Miner Res, 37(1):95\u2013107. https:\/\/doi.org\/10.1002\/jbmr.4458","journal-title":"J Bone Miner Res"},{"issue":"8","key":"785_CR91","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1177\/1066896919857135","volume":"27","author":"AD Ware","year":"2019","unstructured":"Ware AD, Brewer N, Meyers C, et al., 2019. Differential vascularity in genetic and nonhereditary heterotopic ossification. Int J Surg Pathol, 27(8):859\u2013867. https:\/\/doi.org\/10.1177\/1066896919857135","journal-title":"Int J Surg Pathol"},{"issue":"6","key":"785_CR92","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/bcp.13823","volume":"85","author":"KL Wentworth","year":"2019","unstructured":"Wentworth KL, Masharani U, Hsiao EC, 2019. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva. Br J Clin Pharmacol, 85(6): 1180\u20131187. https:\/\/doi.org\/10.1111\/bcp.13823","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"785_CR93","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1002\/jbmr.4711","volume":"37","author":"KL Wentworth","year":"2022","unstructured":"Wentworth KL, Lalonde RL, Groppe JC, et al., 2022. Functional testing of bone morphogenetic protein (BMP) pathway variants identified on whole-exome sequencing in a patient with delayed-onset fibrodysplasia ossificans progressiva (FOP) using ACVR1R206H-specific human cellular and zebrafish models. J Bone Miner Res, 37(11):2058\u20132076. https:\/\/doi.org\/10.1002\/jbmr.4711","journal-title":"J Bone Miner Res"},{"issue":"2","key":"785_CR94","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/bdrc.10010","volume":"69","author":"AD Weston","year":"2003","unstructured":"Weston AD, Hoffman LM, Underhill TM, 2003. Revisiting the role of retinoid signaling in skeletal development. Birth Defects Res Part C Embryo Today, 69(2):156\u2013173. https:\/\/doi.org\/10.1002\/bdrc.10010","journal-title":"Birth Defects Res Part C Embryo Today"},{"issue":"8","key":"785_CR95","doi-asserted-by":"publisher","first-page":"e95042","DOI":"10.1172\/jci.insight.95042","volume":"6","author":"E Williams","year":"2021","unstructured":"Williams E, Bagarova J, Kerr G, et al., 2021. Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. JCI Insight, 6(8):e95042. https:\/\/doi.org\/10.1172\/jci.insight.95042","journal-title":"JCI Insight"},{"key":"785_CR96","doi-asserted-by":"publisher","first-page":"128452","DOI":"10.1016\/j.bmcl.2021.128452","volume":"55","author":"MR Witten","year":"2022","unstructured":"Witten MR, Wu LX, Lai CT, et al., 2022. Inhibition of ALK2 with bicyclic pyridyllactams. Bioorg Med Chem Lett, 55:128452. https:\/\/doi.org\/10.1016\/j.bmcl.2021.128452","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"785_CR97","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.3390\/ijms22073295","volume":"22","author":"HY Xiong","year":"2021","unstructured":"Xiong HY, Veedu RN, Diermeier SD, 2021. Recent advances in oligonucleotide therapeutics in oncology. Int J Mol Sciences, 22(7):3295. https:\/\/doi.org\/10.3390\/ijms22073295","journal-title":"Int J Mol Sciences"},{"key":"785_CR98","doi-asserted-by":"publisher","first-page":"127858","DOI":"10.1016\/j.bmcl.2021.127858","volume":"38","author":"H Yamamoto","year":"2021","unstructured":"Yamamoto H, Sakai N, Ohte S, et al., 2021. Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva. Bioorg Med Chem Lett, 38:127858. https:\/\/doi.org\/10.1016\/j.bmcl.2021.127858","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"785_CR99","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1002\/jbmr.4617","volume":"37","author":"M Yamamoto","year":"2022","unstructured":"Yamamoto M, Stoessel SJ, Yamamoto S, et al., 2022. Overexpression of wild-type ACVR1 in fibrodysplasia ossificans progressiva mice rescues perinatal lethality and inhibits heterotopic ossification. J Bone Miner Res, 37(11): 2077\u20132093. https:\/\/doi.org\/10.1002\/jbmr.4617","journal-title":"J Bone Miner Res"},{"issue":"12","key":"785_CR100","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3390\/md18120606","volume":"18","author":"H Yamazaki","year":"2020","unstructured":"Yamazaki H, Ohte S, Rotinsulu H, et al., 2020. Screening for small molecule inhibitors of BMP-induced osteoblastic differentiation from indonesian marine invertebrates. Mar Drugs, 18(12):606. https:\/\/doi.org\/10.3390\/md18120606","journal-title":"Mar Drugs"},{"issue":"665","key":"785_CR101","doi-asserted-by":"publisher","first-page":"eaaz9368","DOI":"10.1126\/scisignal.aaz9368","volume":"14","author":"JW Yang","year":"2021","unstructured":"Yang JW, Kitami M, Pan HC, et al., 2021. Augmented BMP signaling commits cranial neural crest cells to a chondrogenic fate by suppressing autophagic \u03b2-catenin degradation. Sci Signal, 14(665):eaaz9368. https:\/\/doi.org\/10.1126\/scisignal.aaz9368","journal-title":"Sci Signal"},{"key":"785_CR102","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1038\/s41467-022-33956-9","volume":"13","author":"YS Yang","year":"2022","unstructured":"Yang YS, Kim JM, Xie J, et al., 2022. Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery. Nat Commun, 13:6175. https:\/\/doi.org\/10.1038\/s41467-022-33956-9","journal-title":"Nat Commun"},{"issue":"9","key":"785_CR103","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3390\/biom13091364","volume":"13","author":"YS Yang","year":"2023","unstructured":"Yang YS, Lin CJ, Ma H, et al., 2023. AAV-mediated targeting of the activin A-ACVR1R206H signaling in fibrodysplasia ossificans progressiva. Biomolecules, 13(9):1364. https:\/\/doi.org\/10.3390\/biom13091364","journal-title":"Biomolecules"},{"key":"785_CR104","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13023-023-02708-3","volume":"18","author":"ZQ Ye","year":"2023","unstructured":"Ye ZQ, Wang SY, Shan C, et al., 2023. The serum levels of activin A and bone morphogenetic protein-4 and-6 in patients with fibrodysplasia ossificans progressiva. Orphanet J Rare Dis, 18:111. https:\/\/doi.org\/10.1186\/s13023-023-02708-3","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"785_CR105","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/nm.1888","volume":"14","author":"PB Yu","year":"2008","unstructured":"Yu PB, Deng DY, Lai CS, et al., 2008a. BMP type I receptor inhibition reduces heterotopic ossification. Nat Med, 14(12): 1363\u20131369. https:\/\/doi.org\/10.1038\/nm.1888","journal-title":"Nat Med"},{"issue":"1","key":"785_CR106","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nchembio.2007.54","volume":"4","author":"PB Yu","year":"2008","unstructured":"Yu PB, Hong CC, Sachidanandan C, et al., 2008b. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol, 4(1):33\u201341. https:\/\/doi.org\/10.1038\/nchembio.2007.54","journal-title":"Nat Chem Biol"},{"issue":"2","key":"785_CR107","doi-asserted-by":"publisher","first-page":"a022129","DOI":"10.1101\/cshperspect.a022129","volume":"9","author":"YE Zhang","year":"2017","unstructured":"Zhang YE, 2017. Non-Smad signaling pathways of the TGF-\u03b2 family. Cold Spring Harb Perspect Biol, 9(2):a022129. https:\/\/doi.org\/10.1101\/cshperspect.a022129","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"7","key":"785_CR108","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrclinonc.2016.41","volume":"13","author":"L Zitvogel","year":"2016","unstructured":"Zitvogel L, Rusakiewicz S, Routy B, et al., 2016. Immunological off-target effects of imatinib. Nat Rev Clin Oncol, 13(7): 431\u2013446. https:\/\/doi.org\/10.1038\/nrclinonc.2016.41","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Journal of Zhejiang University-SCIENCE B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2300779.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1631\/jzus.B2300779\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2300779.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T09:02:26Z","timestamp":1746262946000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1631\/jzus.B2300779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":108,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["785"],"URL":"https:\/\/doi.org\/10.1631\/jzus.b2300779","relation":{},"ISSN":["1673-1581","1862-1783"],"issn-type":[{"value":"1673-1581","type":"print"},{"value":"1862-1783","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"29 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yijun ZHOU, Ce SHI, and Hongchen SUN declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"This review does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}